Skip to content
2000
Volume 24, Issue 1
  • ISSN: 1570-159X
  • E-ISSN: 1875-6190

Abstract

Introduction

Chronic insomnia disorder significantly affects cognitive, emotional, and physical health. Recently, the dual orexin receptor antagonist (DORA) daridorexant was approved for treating chronic insomnia in several countries. Given the limited evidence available, expert consensus was sought to clarify key clinical issues, inform practice, and guide future research.

Methods

Thirteen Italian sleep experts employed the Nominal Group Technique (NGT) to identify and rank important clinical questions. The process involved independent thought generation, group discussion, and online voting using a 5-point Likert scale.

Results

The NGT process resulted in 55 statements across five key clinical questions, with relevance scores guiding their categorization into three tiers. Key findings highlight daridorexant’s mechanism of action, safety profile, efficacy on night and day parameters, and suitability for long-term use. The experts emphasized cross-tapering strategies for switching from other hypnotics, the importance of sleep psychoeducation, and using the Insomnia Severity Index and sleep diaries for treatment evaluation.

Discussion

Daridorexant may address insomnia without increasing sedation its dual orexin receptor antagonism. Daridorexant seems to be effective and safe even in special patient populations, such as the elderly and those with comorbid conditions (neurodegenerative disorders and cognitive impairment, comorbid insomnia and sleep apnea, psychiatric conditions and mood disorders, epilepsy, and restless leg syndrome), thus representing a new, promising option for insomnia treatment.

Conclusion

The expert consensus provides a comprehensive framework for daridorexant clinical application, advocating for further research to expand the evidence base and refine best practices, as well as underscoring the importance of a multidisciplinary approach that combines both pharmacological and psychosocial interventions to optimize outcomes.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/011570159X367329250717020016
2025-08-06
2026-02-22

  • From This Site

    /content/journals/cn/10.2174/011570159X367329250717020016
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MorinC.M. JarrinD.C. Epidemiology of insomnia.Sleep Med. Clin.202217217319110.1016/j.jsmc.2022.03.003 35659072
     [Google Scholar]
  2. RiemannD. BenzF. DressleR.J. EspieC.A. JohannA.F. BlankenT.F. LeerssenJ. WassingR. HenryA.L. KyleS.D. SpiegelhalderK. Van SomerenE.J.W. Insomnia disorder: State of the science and challenges for the future.J. Sleep Res.2022314e1360410.1111/jsr.13604 35460140
     [Google Scholar]
  3. MorinC.M. JarrinD.C. IversH. MéretteC. LeBlancM. SavardJ. Incidence, persistence, and remission rates of insomnia over 5 years.JAMA Netw. Open2020311e201878210.1001/jamanetworkopen.2020.18782 33156345
     [Google Scholar]
  4. Diagnostic and statistical manual of mental disorders. American Psychiatric Association: Washington, DC,2013Fifth Edition (DSM-5).10.1176/appi.books.9780890425596
     [Google Scholar]
  5. The Diagnostic and Statistical Manual of Mental Disorders.Washington, DCAmerican Psychiatric Association2022
     [Google Scholar]
  6. International Classification of Sleep Disorders, 3rd ed, text revisionAmerican Academy of Sleep Medicine.ILDarien2023
     [Google Scholar]
  7. Wardle-PinkstonS. SlavishD.C. TaylorD.J. Insomnia and cognitive performance: A systematic review and meta-analysis.Sleep Med. Rev.20194810120510.1016/j.smrv.2019.07.008 31522135
     [Google Scholar]
  8. ShiL. ChenS.J. MaM.Y. BaoY.P. HanY. WangY.M. ShiJ. VitielloM.V. LuL. Sleep disturbances increase the risk of dementia: A systematic review and meta-analysis.Sleep Med. Rev.20184041610.1016/j.smrv.2017.06.010 28890168
     [Google Scholar]
  9. SofiF. CesariF. CasiniA. MacchiC. AbbateR. GensiniG.F. Insomnia and risk of cardiovascular disease: A meta-analysis.Eur. J. Prev. Cardiol.2014211576410.1177/2047487312460020 22942213
     [Google Scholar]
  10. PalaginiL. HertensteinE. RiemannD. NissenC. Sleep, insomnia and mental health.J. Sleep Res.2022314e1362810.1111/jsr.13628 35506356
     [Google Scholar]
  11. HertensteinE. FeigeB. GmeinerT. KienzlerC. SpiegelhalderK. JohannA. Jansson-FröjmarkM. PalaginiL. RückerG. RiemannD. BaglioniC. Insomnia as a predictor of mental disorders: A systematic review and meta-analysis.Sleep Med. Rev.2019439610510.1016/j.smrv.2018.10.006 30537570
     [Google Scholar]
  12. GrandnerM.A. Sleep, health, and society.Sleep Med. Clin.202217211713910.1016/j.jsmc.2022.03.001 35659068
     [Google Scholar]
  13. HafnerM. MartinS. JirkaT. WendyM.T. ChristianV.S. Why sleep matters — the economic costs of insufficient sleep: A cross-country comparative analysis.Santa Monica, CARAND Corporation201610.7249/RR1791
     [Google Scholar]
  14. RiemannD. EspieC.A. AltenaE. ArnardottirE.S. BaglioniC. BassettiC.L.A. BastienC. BerzinaN. BjorvatnB. DikeosD. Dolenc GroseljL. EllisJ.G. Garcia-BorregueroD. GeoffroyP.A. GjerstadM. GonçalvesM. HertensteinE. HoedlmoserK. HionT. HolzingerB. JankuK. Jansson-FröjmarkM. JärnefeltH. JernelövS. JennumP.J. KhachatryanS. KroneL. KyleS.D. LanceeJ. LegerD. LupusorA. MarquesD.R. NissenC. PalaginiL. PaunioT. PerogamvrosL. PevernagieD. SchabusM. ShochatT. SzentkiralyiA. Van SomerenE. van StratenA. WichniakA. VerbraeckenJ. SpiegelhalderK. The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023.J. Sleep Res.2023326e1403510.1111/jsr.14035 38016484
     [Google Scholar]
  15. RiemannD. BaglioniC. BassettiC. BjorvatnB. Dolenc GroseljL. EllisJ.G. EspieC.A. Garcia-BorregueroD. GjerstadM. GonçalvesM. HertensteinE. Jansson-FröjmarkM. JennumP.J. LegerD. NissenC. ParrinoL. PaunioT. PevernagieD. VerbraeckenJ. WeeßH.G. WichniakA. ZavalkoI. ArnardottirE.S. DeleanuO.C. StrazisarB. ZoetmulderM. SpiegelhalderK. European guideline for the diagnosis and treatment of insomnia.J. Sleep Res.201726667570010.1111/jsr.12594 28875581
     [Google Scholar]
  16. EdingerJ.D. ArnedtJ.T. BertischS.M. CarneyC.E. HarringtonJ.J. LichsteinK.L. SateiaM.J. TroxelW.M. ZhouE.S. KazmiU. HealdJ.L. MartinJ.L. Behavioral and psychological treatments for chronic insomnia disorder in adults: An American Academy of Sleep Medicine clinical practice guideline.J. Clin. Sleep Med.202117225526210.5664/jcsm.8986 33164742
     [Google Scholar]
  17. PalaginiL. ManniR. LiguoriC. De GennaroL. GemignaniA. FanfullaF. FerriR. NobiliL. Ferini-StrambiL. Evaluation and management of insomnia in the clinical practice in Italy: A 2023 update from the Insomnia Expert Consensus Group.J. Neurol.202427141668167910.1007/s00415‑023‑12112‑3 38063870
     [Google Scholar]
  18. Daridorexant for treating long-term insomnia. Technology appraisal guidance.2023Available from: https://www.nice.org.uk/guidance/ta922/chapter/1-Recommendations
  19. SateiaM.J. BuysseD.J. KrystalA.D. NeubauerD.N. HealdJ.L. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An American academy of sleep medicine clinical practice guideline.J. Clin. Sleep Med.201713230734910.5664/jcsm.6470 27998379
     [Google Scholar]
  20. MuehlanC. RochC. VaillantC. DingemanseJ. The orexin story and orexin receptor antagonists for the treatment of insomnia.J. Sleep Res.2023326e1390210.1111/jsr.13902 37086045
     [Google Scholar]
  21. Committee for Medicinal Products for Human Use (CHMP).Daridorexant summary of product characteristics.2022Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/quviviq#product-information-section
    [Google Scholar]
  22. Center for Drug Evaluation and ResearchDaridorexant full prescribing information.2022Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214985s000lbl.pdf
    [Google Scholar]
  23. QUVIVIQ Canada Product monograph.Available from: https://www.idorsia.com/documents/com/label/quviviq-product-monograph.pdf
  24. QUVIVIQ Public Summary SwissPAR.Available from: https://www.swissmedic.ch/swissmedic/en/home/about-us/citations/public-summary-swiss-par/public-summary-swiss-par-quviviq.html
  25. Announcement of Application for manufacturing and marketing approval of insomnia.Available from: https://www.mochida.co.jp/english/upload/docs/231031.pdf
  26. JiangF. LiH. ChenY. LuH. NiJ. ChenG. Daridorexant for the treatment of insomnia disorder: A systematic review and meta-analysis of randomized controlled trials.Medicine (Baltimore)20231027e3275410.1097/MD.0000000000032754 36800596
     [Google Scholar]
  27. MignotE. MaylebenD. FietzeI. LegerD. ZammitG. BassettiC.L.A. PainS. KinterD.S. RothT. Safety and efficacy of daridorexant in patients with insomnia disorder: Results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials.Lancet Neurol.202221212513910.1016/S1474‑4422(21)00436‑1 35065036
     [Google Scholar]
  28. DauvilliersY. ZammitG. FietzeI. MaylebenD. Seboek KinterD. PainS. HednerJ. Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder.Ann. Neurol.202087334735610.1002/ana.25680 31953863
     [Google Scholar]
  29. ZammitG. DauvilliersY. PainS. Sebök KinterD. MansourY. KunzD. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder.Neurology20209421e2222e223210.1212/WNL.0000000000009475 32341187
     [Google Scholar]
  30. LedererK. BenesH. FineA. ShoffnerS. BacchelliS. DiazD.C. BatistaJ.E. RowlesR. MarcoT.D. MeinelM. A randomised crossover trial of daridorexant for the treatment of chronic insomnia and nocturia.J. Sleep Res.2025e7000210.1111/jsr.70002 40083090
     [Google Scholar]
  31. KunzD. DauvilliersY. BenesH. García-BorregueroD. PlazziG. Seboek KinterD. ColomaP. RauschM. Sassi-SayadiM. TheinS. Long-term safety and tolerability of daridorexant in patients with insomnia disorder.CNS Drugs20233719310610.1007/s40263‑022‑00980‑8 36484969
     [Google Scholar]
  32. PalaginiL. AlfiG. GurrieriR. AnnuzziE. CarusoV. GambiniM. GrennoG. TrivellaM. PrestaS. MiniatiM. PiniS. PerugiG. GemignaniA. Early experience with the new DORA daridorexant in patients with insomnia disorder and comorbid mental disturbances: Results of a naturalistic study with 3 months follow-up.J. Sleep Res.2024336e1419610.1111/jsr.14196 38522432
     [Google Scholar]
  33. FernandesM. PlacidiF. MercuriN.B. LiguoriC. Daridorexant treatment for chronic insomnia: A real-world retrospective single-center study.Neurol. Sci.20244573443344810.1007/s10072‑024‑07326‑w 38280086
     [Google Scholar]
  34. WinterY. ApelD. GroppaS. Influence of daridorexant on the health-related quality of life in patients with chronic insomnia.2023Available from: https://worldsleepsociety.org/wp-content/uploads/2023/12/WS2023_by_topic_title.pdf
  35. JonesJ. HunterD. Qualitative research: Consensus methods for medical and health services research.BMJ1995311700137638010.1136/bmj.311.7001.376 7640549
     [Google Scholar]
  36. GallagherM. HaresT. SpencerJ. BradshawC. WebbI. The nominal group technique: A research tool for general practice?Fam. Pract.1993101768110.1093/fampra/10.1.76 8477899
     [Google Scholar]
  37. Van de VenA.H. DelbecqA.L. The nominal group as a research instrument for exploratory health studies.Am. J. Public. Health.197262333734210.2105/AJPH.62.3.337 5011164
     [Google Scholar]
  38. GattrellW.T. LogulloP. van ZuurenE.J. PriceA. HughesE.L. BlazeyP. WinchesterC.C. ToveyD. GoldmanK. HunginA.P. HarrisonN. ACCORD (Accurate Consensus Reporting Document): A reporting guideline for consensus methods in biomedicine developed via a modified Delphi.PLoS Med.2024211e100432610.1371/journal.pmed.1004326 38261576
     [Google Scholar]
  39. PallantiS. ZoharJ. KasperS. MöllerH.J. HollanderE. Revisiting benzodiazepines (GABA Enhancers):A transdiagnostic and precision medicine approach.J. Psychiatr. Res.2024170657210.1016/j.jpsychires.2023.11.042 38103451
     [Google Scholar]
  40. PalaginiL. GeoffroyP.A. BalestrieriM. MiniatiM. BiggioG. LiguoriC. MenicucciD. Ferini-StrambiL. NobiliL. RiemannD. GemignaniA. Current models of insomnia disorder: A theoretical review on the potential role of the orexinergic pathway with implications for insomnia treatment.J. Sleep Res.2023324e1382510.1111/jsr.13825 36786121
     [Google Scholar]
  41. SoyaS. SakuraiT. Orexin as a modulator of fear-related behavior: Hypothalamic control of noradrenaline circuit.Brain Res.2020173114603710.1016/j.brainres.2018.11.032 30481504
     [Google Scholar]
  42. ClarkJ.W. BrianM.L. DrummondS.P.A. HoyerD. JacobsonL.H. Effects of orexin receptor antagonism on human sleep architecture: A systematic review.Sleep Med. Rev.20205310133210.1016/j.smrv.2020.101332 32505969
     [Google Scholar]
  43. Di MarcoT. ScammellT.E. MeinelM. Seboek KinterD. DattaA.N. ZammitG. DauvilliersY. Number, duration, and distribution of wake bouts in patients with insomnia disorder: effect of daridorexant and zolpidem.CNS Drugs202337763965310.1007/s40263‑023‑01020‑9 37477771
     [Google Scholar]
  44. RochC. BergaminiG. SteinerM.A. ClozelM. Nonclinical pharmacology of daridorexant: A new dual orexin receptor antagonist for the treatment of insomnia.Psychopharmacology (Berl.)2021238102693270810.1007/s00213‑021‑05954‑0 34415378
     [Google Scholar]
  45. TannenbaumP.L. TyeS.J. StevensJ. GotterA.L. FoxS.V. SavitzA.T. ColemanP.J. UslanerJ.M. KudukS.D. HargreavesR. WinrowC.J. RengerJ.J. Inhibition of orexin signaling promotes sleep yet preserves salient arousability in monkeys.Sleep201639360361210.5665/sleep.5536 26943466
     [Google Scholar]
  46. HintzeJ.P. EdingerJ.D. Hypnotic discontinuation in chronic insomnia.Sleep Med. Clin.202217352353010.1016/j.jsmc.2022.06.014 36150811
     [Google Scholar]
  47. RiemannD. SpiegelhalderK. FeigeB. VoderholzerU. BergerM. PerlisM. NissenC. The hyperarousal model of insomnia: A review of the concept and its evidence.Sleep Med. Rev.2010141193110.1016/j.smrv.2009.04.002 19481481
     [Google Scholar]
  48. HuangZ. LiangP. JiaX. ZhanS. LiN. DingY. LuJ. WangY. LiK. Abnormal amygdala connectivity in patients with primary insomnia: Evidence from resting state fMRI.Eur. J. Radiol.20128161288129510.1016/j.ejrad.2011.03.029 21458943
     [Google Scholar]
  49. ChenM.C. ChangC. GloverG.H. GotlibI.H. Increased insula coactivation with salience networks in insomnia.Biol. Psychol.2014971810.1016/j.biopsycho.2013.12.016 24412227
     [Google Scholar]
  50. LiZ. ChenR. GuanM. WangE. QianT. ZhaoC. ZouZ. BeckT. ShiD. WangM. ZhangH. LiY. Disrupted brain network topology in chronic insomnia disorder: A resting-state fMRI study.Neuroimage Clin.20181817818510.1016/j.nicl.2018.01.012 29387533
     [Google Scholar]
  51. BoofM.L. AlatrachA. UferM. DingemanseJ. Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies.Eur. J. Clin. Pharmacol.201975219520510.1007/s00228‑018‑2559‑5 30284597
     [Google Scholar]
  52. BergerB. KornbergerR. DingemanseJ. Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjects.Eur. Neuropsychopharmacol.2021519010410.1016/j.euroneuro.2021.05.005 34098518
     [Google Scholar]
  53. FerreiraP. FerreiraA.R. BarretoB. FernandesL. Is there a link between the use of benzodiazepines and related drugs and dementia? A systematic review of reviews.Eur. Geriatr. Med.2022131193210.1007/s41999‑021‑00553‑w 34403113
     [Google Scholar]
  54. SminkB.E. EgbertsA.C.G. LusthofK.J. UgesD.R.A. de GierJ.J. The relationship between benzodiazepine use and traffic accidents: A systematic literature review.CNS Drugs201024863965310.2165/11533170‑000000000‑00000 20658797
     [Google Scholar]
  55. MadhusoodananS. BogunovicO.J. Safety of benzodiazepines in the geriatric population.Expert Opin. Drug Saf.20043548549310.1517/14740338.3.5.485 15335303
     [Google Scholar]
  56. FornaroM. CaiazzaC. RossanoF. CilmiF. De PriscoM. VietaE. ThompsonT. SolmiM. CarvalhoA.F. IasevoliF. de BartolomeisA. Residual effects of medications for sleep disorders on driving performance: A systematic review and network meta-analysis of randomized controlled trials.Eur. Neuropsychopharmacol.202481536310.1016/j.euroneuro.2024.01.011 38401406
     [Google Scholar]
  57. SeppalaL.J. WermelinkA.M.A.T. de VriesM. PloegmakersK.J. van de GlindE.M.M. DaamsJ.G. van der VeldeN. BlainH. BousquetJ. BuchtG. Caballero-MoraM.A. van der CammenT. EklundP. Emmelot-VonkM. GustafsonY. HartikainenS. KennyR.A. LaflammeL. LandiF. MasudT. O’Byrne-MaguireI. PetrovicM. RodriguezL. SeppäläL. SvenssonO. SzczerbińskaK. ThalerH. van der VeldeN. Fall-risk-increasing drugs: A systematic review and meta-analysis: II. Psychotropics.J. Am. Med. Dir. Assoc.2018194371.e11371.e1710.1016/j.jamda.2017.12.098 29402652
     [Google Scholar]
  58. LiS.B. DamonteV.M. ChenC. WangG.X. KebschullJ.M. YamaguchiH. BianW.J. PurmannC. PattniR. UrbanA.E. MourrainP. KauerJ.A. ScherrerG. de LeceaL. Hyperexcitable arousal circuits drive sleep instability during aging.Science20223756583eabh302110.1126/science.abh3021 35201886
     [Google Scholar]
  59. FietzeI. BassettiC.L.A. MaylebenD.W. PainS. SeboekK.D. McCallW.V. Efficacy and safety of daridorexant in older and younger adults with insomnia disorder: a secondary analysis of a randomised placebo-controlled trial.Drugs Aging2022391079581010.1007/s40266‑022‑00977‑4 36098936
     [Google Scholar]
  60. PreskornS.H. Comparative pharmacology of the 3 marketed dual orexin antagonists—daridorexant, lemborexant, and suvorexant—part 2. principal drug metabolizing enzyme, drug-drug interactions, and effects of liver and renal impairment on metabolism.J. Psychiatr. Pract.2023291384110.1097/PRA.0000000000000690 36649550
     [Google Scholar]
  61. ChaputJ.P. DutilC. Sampasa-KanyingaH. Sleeping hours: What is the ideal number and how does age impact this?Nat. Sci. Sleep20181042143010.2147/NSS.S163071 30568521
     [Google Scholar]
  62. WatsonN.F. BencaR.M. KrystalA.D. McCallW.V. NeubauerD.N. Alliance for sleep clinical practice guideline on switching or deprescribing hypnotic medications for insomnia.J. Clin. Med.2023127249310.3390/jcm12072493 37048577
     [Google Scholar]
  63. PollmannA.S. MurphyA.L. BergmanJ.C. GardnerD.M. Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: A scoping review.BMC Pharmacol. Toxicol.20151611910.1186/s40360‑015‑0019‑8 26141716
     [Google Scholar]
  64. LegerD. FietzeI. PainS. KinterD.S. FlamionB. MignotE. 348 absence of withdrawal symptoms and rebound insomnia upon discontinuation of daridorexant in patients with insomnia.Sleep202144A13910.1093/sleep/zsab072.347
     [Google Scholar]
  65. CarpiM. PalaginiL. FernandesM. CalvelloC. GeoffroyP.A. MiniatiM. PiniS. GemignaniA. MercuriN.B. LiguoriC. Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities.Neuropharmacology202424510981510.1016/j.neuropharm.2023.109815 38114045
     [Google Scholar]
  66. LiguoriC. PlacidiF. IzziF. SpanettaM. MercuriN.B. Di PucchioA. Sleep dysregulation, memory impairment, and CSF biomarkers during different levels of neurocognitive functioning in Alzheimer’s disease course.Alzheimers Res. Ther.2020121510.1186/s13195‑019‑0571‑3 31901236
     [Google Scholar]
  67. LiguoriC. NuccetelliM. IzziF. SancesarioG. RomigiA. MartoranaA. AmorosoC. BernardiniS. MarcianiM.G. MercuriN.B. PlacidiF. Rapid eye movement sleep disruption and sleep fragmentation are associated with increased orexin-A cerebrospinal-fluid levels in mild cognitive impairment due to Alzheimer’s disease.Neurobiol. Aging20164012012610.1016/j.neurobiolaging.2016.01.007 26973111
     [Google Scholar]
  68. LiguoriC. RomigiA. NuccetelliM. ZanninoS. SancesarioG. MartoranaA. AlbaneseM. MercuriN.B. IzziF. BernardiniS. NittiA. SancesarioG.M. SicaF. MarcianiM.G. PlacidiF. Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease.JAMA Neurol.201471121498150510.1001/jamaneurol.2014.2510 25322206
     [Google Scholar]
  69. BerteottiC. CalvelloC. LiguoriC. Role of the orexin system in the bidirectional relation between sleep and epilepsy: New chances for patients with epilepsy by the antagonism to orexin receptors?Epilepsia20236481991200510.1111/epi.17661 37212716
     [Google Scholar]
  70. BoofM.L. DingemanseJ. LedererK. FietzeI. UferM. Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea.Sleep2021446zsaa27510.1093/sleep/zsaa275 33305817
     [Google Scholar]
  71. BoofM.L. UferM. FietzeI. PépinJ.L. GuernA.S. LemoineV. DingemanseJ. Assessment of the effect of the dual orexin receptor antagonist daridorexant on various indices of disease severity in patients with mild to moderate obstructive sleep apnea.Sleep Med.20229241110.1016/j.sleep.2021.11.015 35306405
     [Google Scholar]
  72. SweetmanA. LackL. BastienC. Co-morbid insomnia and sleep apnea (COMISA): Prevalence, consequences, methodological considerations, and recent randomized controlled trials.Brain Sci.201991237110.3390/brainsci9120371 31842520
     [Google Scholar]
  73. BoofM.L. LedererK. PépinJ.L. FietzeI. DingemanseJ. Repeated dosing (5 nights) of 50 mg daridorexant in patients with severe obstructive sleep apnea: Effect on sleep-disordered breathing and sleep.2023Available from: https://worldsleepsociety.org/wp-content/uploads/2023/12/WS2023_by_topic_title.pdf
  74. CarneyC.E. BuysseD.J. Ancoli-IsraelS. EdingerJ.D. KrystalA.D. LichsteinK.L. MorinC.M. The consensus sleep diary: Standardizing prospective sleep self-monitoring.Sleep201235228730210.5665/sleep.1642 22294820
     [Google Scholar]
  75. BastienC. VallièresA. MorinC.M. Validation of the insomnia severity index as an outcome measure for insomnia research.Sleep Med.20012429730710.1016/S1389‑9457(00)00065‑4 11438246
     [Google Scholar]
  76. MorinC.M. BellevilleG. BélangerL. IversH. The insomnia severity index: psychometric indicators to detect insomnia cases and evaluate treatment response.Sleep201134560160810.1093/sleep/34.5.601 21532953
     [Google Scholar]
  77. CastronovoV. GalbiatiA. MarelliS. BrombinC. CugnataF. GiarolliL. AnelliM.M. RinaldiF. Ferini-StrambiL. Validation study of the italian version of the insomnia severity index (ISI).Neurol. Sci.20163791517152410.1007/s10072‑016‑2620‑z 27234459
     [Google Scholar]
  78. SelsickH. HeidbrederA. EllisJ. Ferini-StrambiL. García-BorregueroD. LeontiouC. MakM.S.B. O’ReganD. ParrinoL. Assessment and management of chronic insomnia disorder: An algorithm for primary care physicians.BMC Prim. Care202425113810.1186/s12875‑024‑02381‑w 38671358
     [Google Scholar]
  79. LiguoriC. MombelliS. FernandesM. ZucconiM. PlazziG. Ferini-StrambiL. LogroscinoG. MercuriN.B. FilardiM. The evolving role of quantitative actigraphy in clinical sleep medicine.Sleep Med. Rev.20236810176210.1016/j.smrv.2023.101762 36773596
     [Google Scholar]
/content/journals/cn/10.2174/011570159X367329250717020016
Loading
Daridorexant and Insomnia in Clinical Practice: A Nominal Group Technique Consensus Study among Italian Sleep and Insomnia Experts
Curr. Neuropharmacol. 24, 135 (2026); https://doi.org/10.2174/011570159X367329250717020016
/content/journals/cn/10.2174/011570159X367329250717020016
/content/journals/cn/10.2174/011570159X367329250717020016
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): chronic insomnia disorder; daridorexant; DORA; Insomnia; insomnia treatment; orexin; sleep health

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test